Michael Leonard Ritchey

Michael Leonard Ritchey (born December 27, 1954) is an American pediatric urologist and academic researcher known for his contributions to the treatment of Wilms' tumor.[1][2] He previously served as Chief Medical Officer at Phoenix Children’s Hospital.[3][4]

Early life and education

Ritchey completed his undergraduate degree at the University of Southwestern Louisiana in 1975 and earned his M.D. from Louisiana State University School of Medicine in 1979.[5] He completed his residency at Wilford Hall USAF Medical Center and a fellowship in pediatric urology at the Mayo Clinic.[6]

Career

He began his career in the United States Air Force, receiving the Meritorious Service Medal for his contributions.[7] He later held academic positions at the University of Michigan[2] and the University of Texas Medical School,[2] where he directed the Division of Urology. Since 2011, Ritchey has been affiliated with Phoenix Children’s Hospital, becoming Chief Medical Officer in 2018.

He was a contributor to the National Wilms Tumor Study Group[8] and played a key role in modern treatment protocols for this pediatric kidney cancer. His contributions extend to clinical guidelines that have improved outcomes for children globally. His work includes over 200 peer-reviewed publications,[8] book chapters, and editorials.[3]

Research and publications

Ritchey has contributed to pediatric oncology research, including work with the National Wilms Tumor Study Group.[8] His publications focus on nephroblastoma, pediatric urology, and long-term outcomes of childhood cancer treatments. He has served on editorial boards, including the Journal of Urology.[8][9][5]

References

  1. ^ "Leadership Team". Phoenix Children's Hospital. Retrieved 2025-04-24.
  2. ^ a b c "Urology Research | University of Michigan Medical School". medschool.umich.edu. Retrieved 2025-04-24.
  3. ^ a b "Michael L. Ritchey". Scilit. Retrieved 8 May 2025.
  4. ^ Green, D. M.; Breslow, N. E.; Beckwith, J. B.; Ritchey, M. L.; Shamberger, R. C.; Haase, G. M.; D'Angio, G. J.; Perlman, E.; Donaldson, M.; Grundy, P. E.; Weetman, R.; Coppes, M. J.; Malogolowkin, M.; Shearer, P.; Coccia, P. (2001-09-01). "Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group". Journal of Clinical Oncology. 19 (17): 3719–3724. doi:10.1200/JCO.2001.19.17.3719. ISSN 0732-183X. PMID 11533093.
  5. ^ a b "Michael L. Ritchey. Pediatric Medalist 2019. Section on Urology American Academy of Pediatrics" (PDF). spuonline.org. Retrieved 2025-04-28.
  6. ^ "Michael L. Ritchey | Wilford Hall Medical Center | 1 Publications | 20 Citations | Related Authors". SciSpace - Author. Retrieved 2025-04-24.
  7. ^ https://www.jpurol.com/article/S1477-5131(20)30012-7/pdf
  8. ^ a b c d Ritchey, Michael L.; Shamberger, Robert C.; Hamilton, Thomas; Haase, Gerald; Argani, Pedram; Peterson, Susan (October 2005). "Fate of bilateral renal lesions missed on preoperative imaging: a report from the National Wilms Tumor Study Group". The Journal of Urology. 174 (4 Pt 2): 1519–1521, discussion 1521. doi:10.1097/01.ju.0000179536.97629.c5. ISSN 0022-5347. PMID 16148643.
  9. ^ Grundy, Paul E.; Breslow, Norman E.; Li, Sierra; Perlman, Elizabeth; Beckwith, J. Bruce; Ritchey, Michael L.; Shamberger, Robert C.; Haase, Gerald M.; D'Angio, Giulio J.; Donaldson, Milton; Coppes, Max J.; Malogolowkin, Marcio; Shearer, Patricia; Thomas, Patrick R. M.; Macklis, Roger (2005-10-10). "Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group". Journal of Clinical Oncology. 23 (29): 7312–7321. doi:10.1200/JCO.2005.01.2799. ISSN 0732-183X. PMID 16129848.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.